{"entity":{"id":"nct01772420","kind":"trial","name":"Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia","aka":[],"tldr":"A phase 2 trial of Eltrombopag and Lenalidomide in Leukaemia, run by Albert Einstein College of Medicine, completed.","summary":"Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia is a phase 2 interventional study registered as NCT01772420 by Albert Einstein College of Medicine, with 52 participants recorded, started 2012-10 and reaching its primary completion in 2020-07-09. Interventions recorded: Eltrombopag Olamine, Laboratory Biomarker Analysis, Lenalidomide. Conditions recorded: Adult Myelodysplastic Syndrome, Anemia, Chronic Myelomonocytic Leukemia.\n\nLinked to the drug Eltrombopag because the registry names it among its interventions and Leukaemia among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT01772420","url":"https://clinicaltrials.gov/study/NCT01772420"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["leukaemia"],"sections":[],"technologies":[],"targets":[],"drugs":["eltrombopag","lenalidomide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01772420","phase":"2","setting":"Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia in Low or Intermediate I Myelodysplastic Syndrome (MDS)","sponsor":"Albert Einstein College of Medicine","started":"2012-10","yearReported":2023,"enrolled":52,"enrolledBasis":"registry","outcomes":[{"endpoint":"Number of Patients Demonstrating Overall Hematologic Improvement (HI)","primary":true,"unit":"participants","arms":[{"name":"Arm A (Platelets > 50,000 k/uL) LEN Initiation","n":16,"value":6,"note":"Figures from the ClinicalTrials.gov results section (first posted 2023-07-27), not from a publication"},{"name":"Arm B (Platelets < 50,000 k/uL) ELT Initiation With Potential LEN Combination","n":15,"value":5},{"name":"Arm C (Platelets < 50,000 k/uL) ELT Monotherapy","n":21,"value":7}],"source":"https://clinicaltrials.gov/study/NCT01772420?tab=results"}]},"route":"/trials/nct01772420/","neighbours":{"cancer":[{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"}],"drug":[{"id":"eltrombopag","kind":"drug","name":"Eltrombopag","route":"/drugs/eltrombopag/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"}]}}